MorphoSys Reports Promising Pre-clinical Data for MOR202
Combination Studies to be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)
MorphoSys AG announced promising pre-clinical data on its proprietary drug candidate MOR202, a HuCAL-derived, fully human anti-CD38 antibody. Studies showed that by combining MOR202 with each of two approved drugs for the treatment of multiple myeloma, the anti-cancer activity of the antibody could be enhanced. The effects were seen in in vitro and in vivo models of the disease. The pre-clinical data will be presented at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 3-7, 2011, at the McCormick Place Convention Center in Chicago.
"The synergistic effects that we've seen in pre-clinical studies are very encouraging and point towards a potential clinical use of MOR202," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "We look forward to evaluating MOR202 in a phase 1/2a clinical trial in patients with multiple myeloma, which we expect to start shortly."
In vitro, MOR202 mediates the killing of multiple myeloma cells by antibody-dependent cellular cytotoxicity (ADCC). In combination with the drug bortezomib (Velcade®), MOR202 displayed an enhanced direct cytotoxic effect on multiple myeloma cells. The drug lenalidomide (Revlimid®) synergistically enhanced MOR202 activity on multiple myeloma cells by several mechanisms, including direct cytotoxicity, activation of effector cells and increased CD38 expression levels on the tumor cell surface.
In an in vivo mouse model of multiple myeloma, MOR202 reduces tumor load as well as tumor-mediated bone destruction. In this model, MOR202 in combination with either bortezomib or lenalidomide completely abolished bone destruction in a synergistic manner. These findings support further investigation of MOR202 combination regimens in clinical trials.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous